Mindwalk Holdings Corp. key statistics and ratios
In fiscal 2026, Mindwalk Holdings Corp. had return on equity of -78.5%, a net margin of -89.7%, debt equal to 0.0% of equity and a current ratio of 2.80. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2020Apr 2020 | 2021Apr 2021 | 2022Apr 2022 | 2023Apr 2023 | 2024Apr 2024 | 2025Apr 2025 | 2026Apr 2026 |
|---|---|---|---|---|---|---|---|
| Gross margin | 57.1% | 64.4% | 56.7% | 56.0% | 39.8% | 53.9% | 58.8% |
| Net margin | −35.2% | −41.0% | −86.3% | −128.5% | −254.1% | −284.5% | −89.7% |
| Free-cash-flow margin | −12.6% | −11.0% | −56.7% | −103.2% | −44.6% | −67.8% | −82.7% |
| Return on equity | −34.1% | −19.6% | −25.3% | −39.2% | −56.0% | −100.8% | −78.5% |
| Return on assets | −18.9% | −15.2% | −20.9% | −30.6% | −38.3% | −57.2% | −42.2% |
| Asset turnover | 0.54 | 0.37 | 0.24 | 0.24 | 0.15 | 0.20 | 0.47 |
| Current ratio | 0.97 | 8.05 | 4.03 | 2.84 | 1.41 | 2.08 | 2.80 |
| Debt to equity | 2.1% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| R&D as % of revenue | 3.2% | 11.0% | 39.6% | 68.2% | 36.4% | 39.6% | 31.7% |
| Capital spending as % of revenue | 2.7% | 7.7% | 5.5% | 7.2% | 13.6% | 7.5% | 2.6% |
Financial health
- Short-term assets cover short-term liabilities $12m of assets due within a year against $4m of liabilities due within a year.
- Short-term assets cover long-term liabilities $12m short-term assets against $3m of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Surrozen, Inc. statistics
- Relay Therapeutics, Inc. statistics
- Caribou Biosciences, Inc. statistics
- Opus Genetics, Inc. statistics
- Lineage Cell Therapeutics, Inc. statistics
Head to head: HYFT vs SRZNHYFT vs RLAYCRBU vs HYFTHYFT vs IRD
More: Biotechnology stocks compared, Health Care sector, rankings of US companies